Full Breakdown
Trump Administration Plans to End Medicare Part D Subsidies by 2027
7/30/2026, 4:08:49 AM
Policy Change Overview
The Trump administration announced that the federal subsidies that lower premiums for Medicare Part D prescription-drug plans will expire at the end of the current year, with the change taking effect in 2027. Enrollees will receive notice of the new monthly costs later this fall. The decision was first reported by the *Wall Street Journal*.
Background and Recent Context
Medicare Part D provides prescription-drug coverage to tens of millions of older and disabled Americans. Since the passage of the Affordable Care Act (ACA), ACA subsidies have helped reduce out-of-pocket premiums for marketplace plans, but those subsidies have now expired. Trump officials have criticized the Biden administration’s Inflation Reduction Act, arguing that it “bailed out” major insurers and increased premiums, while the Biden administration highlighted the law’s drug-price-negotiation provisions.
Financial Impact and Projected Cost Changes
The Centers for Medicare & Medicaid Services (CMS) currently pays billions of dollars to insurers as a subsidy that keeps the average Part D premium at about $36 per beneficiary per month, according to the health-policy nonprofit Kaiser Family Foundation (KFF). Ending the subsidies could raise premiums for roughly half of recipients, with KFF estimating possible increases of up to $20 per month for some beneficiaries. Administration officials suggest that most seniors will see premium changes of less than $10 per month.
Official Statements from Administration Officials
CMS Administrator Mehmet Oz said the administration is “stabilizing the market” and that the subsidy “is no longer needed.” He added that the policy will continue to promote lower drug prices through “most-favored-nation” (MFN) deals, which aim to align U.S. drug prices with those in other countries, and that seniors will retain access to low-cost plans, including a $50-per-month price for GLP-1 medications.
Potential Implications for Seniors and the Health-Care Market
If the subsidies are removed, higher premiums could increase out-of-pocket costs for many seniors, potentially affecting medication adherence. The administration’s emphasis on MFN agreements and continued price-lowering initiatives suggests an alternative strategy to control drug costs, though the effectiveness of those measures remains to be observed as the 2027 implementation date approaches.
